Search Results

Ordering information regarding a Deamidated Gliadin Peptide (DGP) Antibody, IgA test for Clinical Diagnostic Laboratories. Deamidated Gliadin Peptide (DGP) Antibody, IgA Ordering Recommendation Acceptable single screening test for celiac disease. IgA testing recommended to identify IgA deficiency. Use IgA test in individuals who are IgA competent. May be useful in diagnosing children <2 years who test negative for tTG and EMA antibodies. May aid in monitoring adherence to gluten-free diet. Celiac Disease Reflexive Cascade (2008114 ) or Tissue Transglutaminase (tTG) Antibody, IgA (0097709 ) is the preferred test for screening patients with suspected celiac disease. Mnemonic Methodology Semi-Quantitative Enzyme-Linked Immunosorbent Assay Performed Mon-Sat Reported 1-2 Days New York DOH Approval Status This test is New York DOH approved. Specimen Required Patient Preparation: Collect: Serum separator tube (SST). Specimen Preparation: Separate serum from cells ASAP or within 2 hours of collection. Transport 0.5 mL serum. (Min: 0.3 mL) Storage/Transport Temperature: Refrigerated Unacceptable Conditions: Plasma or other body fluids. Contaminated, hemolyzed, grossly icteric, or grossly lipemic specimens. Remarks: Plasma. Hemolyzed or severely lipemic specimens. Stability: After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year Reference Interval 19 Units or less 20-30 Units Negative Weak Positive 31 Units or greater Positive Interpretive Data Note Human recombinant tTG antigen is utilized in this assay CPT Code 86258 Components Component Chart Name Deamidated Gliadin Peptide (DGP) Ab, IgA Component Test Code 0051357 LOINC 63453-5 Aliases Celiac Disease Antibodies Coeliac Disease Antib odies Deamidated Gliadin Antibodies (DGP) Deaminated Gliadin Peptide Antibodies DGP DGP Ab DGP IgA

Services for Government Agencies Clinical Diagnostics Laboratories does not currently work with any government agencies but we are registered in the same database and are a female-owned and operated, minority company. Clinical Diagnostics Laboratories is always available and open for opportunities. If you're interested in learning more about our services or are interested in working with us, please contact us for more information. CONTACT US

Ordering information regarding a Cardiolipin Antibody, IgA test for Clinical Diagnostic Laboratories. Cardiolipin Antibody, IgA Ordering Recommendation Preferred second-line test when seronegative antiphospholipid syndrome (APS) is strongly suspected. Order incrementally or concurrently with other noncriteria antiphospholipid antibody tests. Mnemonic CARDIO IGA Performed Mon-Sat Methodology Semi-Quantitative Enzyme-Linked Immunosorbent Assay Reported 1-2 days New York DOH Approval Status This test is New York DOH approved. Specimen Required Patient Preparation: Collect: Serum separator tube. Specimen Preparation: Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to a Standard Transport Tube. (Min: 0.3 mL) Storage/Transport Temperature: Refrigerated. Unacceptable Conditions: Plasma or other body fluids. Contaminated, heat-inactivated, hemolyzed, or lipemic specimens. Remarks: Stability: After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles) Reference Interval <=12 MPL Negative 13-19 MPL Indeterminate 20-80 MPL Low to Moderately Positive 81 MPL or above High Positive Interpretive Data The persistent presence of IgG and/or IgM cardiolipin (CL) antibodies in moderate or high levels (greater than 40 GPL and/or greater than 40 MPL units) is a laboratory criterion for the diagnosis of antiphospholipid syndrome (APS). Persistence is defined as moderate or high levels of IgG and/or IgM CL antibodies detected in two or more specimens drawn at least 12 weeks apart (J Throm Haemost. 2006;4:295-306). Lower positive levels of IgG and/or IgM CL antibodies (above cutoff but less than 40 GPL and/or less than 40 MPL units) may occur in patients with the clinical symptoms of APS; therefore, the actual significance of these levels is undefined. Results should not be used alone for diagnosis and must be interpreted in light of APS-specific clinical manifestations and/or other criteria phospholipid antibody tests. Compliance Category: FDA Note MPL = IgM phospholipid units CPT Code 86147 Components Component Chart Name Cardiolipin Antibody IgM Component Test Code 0050902 LOINC 3182-3 Aliases ACA aCL aCL Antibody aCL IgG Anti-Cardiolipin Anticardiolipin Anticardiolipin Antibodies Cardiolip

Ordering information regarding a Serine Proteinase 3 (PR3) Antibody for Clinical Diagnostic Laboratories. Serine Proteinase 3 (PR3) Antibody Ordering Recommendation When used in conjunction with other autoantibody tests (ANCA, MPO), may aid in differentiating suspected Wegener granulomatosis (WG) from other vasculitides. May be useful to monitor patients with PR3 antibodies. Panel tests are available. For the workup of suspected vasculitis, refer to ANCA-Associated Vasculitis Profile (ANCA/MPO/PR3) (3003745 ). For patients with a history of vasculitis, refer to Myeloperoxidase (MPO) Antibody and Serine Proteinase 3 (PR3) Antibody with Reflex to Anti-Neutrophil Cytoplasmic Antibody, IgG by IFA (3003746 ). Mnemonic PR3 Performed Mon-Sat Methodology Semi-Quantitative Multiplex Bead Assay Reported 1-2 Days New York DOH Approval Status This test is New York DOH approved. Specimen Required Patient Preparation: Collect: Serum separator tube. Specimen Preparation: Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to a Standard Transport Tube. (Min: 0.2 mL) Storage/Transport Temperature: Refrigerated. Unacceptable Conditions: Plasma, urine, or other body fluids. Contaminated, hemolyzed, or severely lipemic specimens., icteric, or lipemic specimens. Remarks: Stability: After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles) Reference Interval 19 AU/mL or less Negative 20-25 AU/mL 26 AU/mL or greater Equivocal Positive Interpretive Data Approximately 85% of patients with a C-ANCA pattern by IFA have antibodies specific for PR3. Compliance Category: FDA Note CPT Code 83516 Components Component Chart Name Serine Proteinase 3 (PR3) Ab, IgG Component Test Code 0050527 LOINC 6968-2 Aliases PR3 PR3 Ab PR3 IgG Antibodies

Ordering information regarding a Hemoglobin A1C test for Clinical Diagnostic Laboratories. Hemoglobin A1C Ordering Recommendation The Hemoglobin A1c test is a vital tool for diagnosing and monitoring diabetes mellitus, as well as assessing prediabetes. Diagnostic levels are marked by values greater than or equal to 6.5%, while monitoring involves tracking long-term glycemic control in diabetes patients. Additionally, values between 5.7% and 6.4% signal an increased risk of developing diabetes. For patients with hemoglobin variants lacking hemoglobin A, the Fructosamine test is preferred for monitoring long-term glycemic control. Mnemonic Methodology Quantitative Capillary Electrophoresis Performed Mon-Sat Reported Within 1-2 days New York DOH Approval Status This test is New York DOH approved. Specimen Required Patient Preparation: Collect: Lavender (EDTA) Specimen Preparation: Transport whole blood in original tube. (Min: 1 mL) Storage/Transport Temperature: Refrigerated. Unacceptable Conditions: Tissue or urine. Samples frozen after 8 hrs of collection and samples frozen at temperatures less than -70C. Remarks: Stability: Ambient: 72 hours; Refrigerated: 1 week; Frozen: 3 months (Must be frozen within 8 hrs of collection at -70 to -80C) Reference Interval Components Available Separately Reference Interval No Hemoglobin A1C Less than 5.7 percent No Estimated Average Glucose By report Interpretive Data HbA1c values of 5.7-6.4 percent indicate an increased risk for developing diabetes mellitus. HbA1c values greater than or equal to 6.5 percent are diagnostic of diabetes mellitus. For diagnosis of diabetes in individuals without unequivocal hyperglycemia, results should be confirmed by repeat testing. Note This assay accurately measures hemoglobin A1c even in the presence of hemoglobin variants, provided hemoglobin A is present. For patients with known hemoglobin variants who lack hemoglobin A, it is recommended to monitor long-term glycemic control using the Fructosamine test CPT Code 83036 Components Component Test Code 0070427 0070428 Component Chart Name Estimated Average Glucose LOINC Hemoglobin A1C 27353-2 4548-4 Aliases Hemoglobin A1C A1C A1C Hemoglobin Glycated Hemoglobin Glyco HGB Glyco-Hb Glycosylated Hemoglobin HA1C HbA1c Hemoglobin A1C Hemoglobin A1C, Blood

Ordering information regarding a Cardiolipin Antibody, IgM test for Clinical Diagnostic Laboratories. Beta-2 Glycoprotein 1 Antibody, IgA Ordering Recommendation Preferred second-line test when seronegative antiphospholipid syndrome (APS) is strongly suspected. Order incrementally or concurrently with other noncriteria antiphospholipid antibody tests. May also be useful in estimating risk of thrombosis and/or pregnancy-related morbidity in patients with SLE. Mnemonic B2GPI A Performed Mon-Sat Methodology Semi-Quantitative Enzyme-Linked Immunosorbent Assay Reported 1-2 days New York DOH Approval Status This test is New York DOH approved. Specimen Required Patient Preparation: Collect: Serum separator tube. Specimen Preparation: Separate serum from cells ASAP or within 2 hours of collection. Storage/Transport Temperature: Refrigerated. Unacceptable Conditions: Plasma or other body fluids. Contaminated, hemolyzed, grossly icteric, or severely lipemic specimens. Remarks: Stability: After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles) Reference Interval <=20 SAU Interpretive Data Compliance Category: FDA Note MPL = IgM phospholipid units CPT Code 86146 Components Component Chart Name B2Glycoprotein 1, IgA Antibody Component Test Code 0050324 LOINC 21108-6 Aliases Anti-B2-Glycoprotein 1 Anti-B2-Glycoprotein I Anti-B2-GP 1 Anti-B2-GP I Anti-B2-GP1 Anti-B2-GPI Anti-Beta-2-Glycoprotein I APOH Apolipoprotein H B2 IgA B2-glycoprotein 1 IgA B2GP1 IgA Beta 2GP1 Ab

Ordering information regarding a Cardiolipin Antibody, IgM test for Clinical Diagnostic Laboratories. Cardiolipin Antibody, IgM Ordering Recommendation Acceptable initial test when antiphospholipid syndrome (APS) is highly suspected. Order with Lupus Anticoagulant Reflexive Panel (0030181 ) and Beta-2 Glycoprotein 1 Antibodies, IgG and IgM (0050321 ). Cardiolipin Antibodies, IgG and IgM (0099344 ) is preferred. Mnemonic AC-IGM Performed Mon-Sat Methodology Semi-Quantitative Enzyme-Linked Immunosorbent Assay Reported 1-2 days New York DOH Approval Status This test is New York DOH approved. Specimen Required Patient Preparation: Collect: Serum separator tube. Specimen Preparation: Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to a Standard Transport Tube. (Min: 0.3 mL) Storage/Transport Temperature: Refrigerated. Unacceptable Conditions: Plasma or other body fluids. Contaminated, heat-inactivated, hemolyzed, or lipemic specimens. Remarks: Stability: After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year Reference Interval <=12 MPL Negative 13-19 MPL Indeterminate 20-80 MPL Low to Moderately Positive 81 MPL or above High Positive Interpretive Data The persistent presence of IgG and/or IgM cardiolipin (CL) antibodies in moderate or high levels (greater than 40 GPL and/or greater than 40 MPL units) is a laboratory criterion for the diagnosis of antiphospholipid syndrome (APS). Persistence is defined as moderate or high levels of IgG and/or IgM CL antibodies detected in two or more specimens drawn at least 12 weeks apart (J Throm Haemost. 2006;4:295-306). Lower positive levels of IgG and/or IgM CL antibodies (above cutoff but less than 40 GPL and/or less than 40 MPL units) may occur in patients with the clinical symptoms of APS; therefore, the actual significance of these levels is undefined. Results should not be used alone for diagnosis and must be interpreted in light of APS-specific clinical manifestations and/or other criteria phospholipid antibody tests. Compliance Category: FDA Note MPL = IgM phospholipid units CPT Code 86147 Components Component Chart Name Cardiolipin Antibody IgM Component Test Code 0050902 LOINC 3182-3 Aliases ACA aCL aCL Antibody aCL IgG Anti-Cardiolipin Anticardiolipin Anticardiolipin Antibodies Cardiolip

Ordering information regarding a Allergen, Food, Egg Whole test for Clinical Diagnostic Laboratories. Allergen, Food, Egg Whole Ordering Recommendation Not recommended for initial thyroid disorders testing. Distinguish thyroid autoimmune disorders from nonautoimmune disease or hypothyroidism. Mnemonic EGGWHOLE Methodology Quantitative ImmunoCAP Fluorescent Enzyme Immunoassay Performed Mon-Sat Reported 1-3 days New York DOH Approval Status This test is New York DOH approved. Specimen Required Patient Preparation: Multiple patient encounters should be avoided. Collect: Serum separator tube. Specimen Preparation: Separate serum from cells ASAP or within 2 hours of collection. Storage/Transport Temperature: Refrigerated. Unacceptable Conditions: Grossly hemolyzed or lipemic specimens. Remarks: Stability: After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year Reference Interval Probability of IgE Mediated Clinical Reaction Reporting Range (reported in kU/L) Class Scoring No significant level detected Less than 0.10 0 0.10 - 0.34 0.35 - 0.70 Clinical relevance undetermined Low 0/1 1 0.71 - 3.50 3.51 - 17.50 Moderate High 2 3 17.51 - 50.00 50.01 - 100.00 Very high Very high 4 5 Greater than 100.00 Very high 6 Interpretive Data Allergen results of 0.10-0.34 kU/L are intended for specialist use as the clinical relevance is undetermined. Even though increasing ranges are reflective of increasing concentrations of allergen-specific IgE, these concentrations may not correlate with the degree of clinical response or skin testing results when challenged with a specific allergen. The correlation of allergy laboratory results with clinical history and in vivo reactivity to specific allergens is essential. A negative test may not rule out clinical allergy or even anaphylaxis. Compliance Category: FDA Note Components CPT Code 86003 Component Chart Name Allergen, Food, Egg Whole IgE Component Test Code 0055381 LOINC 7291-8 Aliases ImmunoCAP f245

Clinical Diagnostic Laboratories provides fast, reliable lab testing for Skilled Nursing Facilities in the DMV area. From routine blood work to infectious disease panels, mobile phlebotomy, and customized testing solutions, we help nursing homes deliver better resident care. Why You Should Choose Clinical Diagnostic Laboratories FAST TURNAROUND TIMES Get results within 24–48 hours, helping your nursing home make faster, informed care decisions. CUSTOMIZED TESTING PANELS We design testing panels tailored to your residents’ unique needs, ensuring the right answers every time. MOBILE PHLEBOTOMY Our skilled team comes directly to your facility, reducing stress for residents and saving staff valuable time. HIPAA COMPLIANT We safeguard all patient information with the highest standards of security and confidentiality. REGULATORY COMPLIANCE CDL meets all federal and state regulations, giving your facility peace of mind and audit-ready confidence. DEDICATED ACCOUNT MANAGER Every partner receives a dedicated account manager to ensure smooth communication and personalized support. SIMPLE REPORTING Our clear, easy-to-read reports help your staff make confident care decisions without confusion. EASY TO ACCESS PATIENT PORTAL Residents and providers can securely view results anytime through our convenient online portal. Lab Testing Designed for Skilled Nursing Facilities To play, press and hold the enter key. To stop, release the enter key. Experience Expert Lab Testing Services Whether your Skilled Nursing Facility requires routine blood work or advanced infectious disease testing, Clinical Diagnostic Laboratories is here to support you. Contact us today to schedule a consultation or explore our full range of services. Contact Us

Ordering information regarding a Tissue Transglutaminase (tTG) IgG test for Clinical Diagnostic Laboratories. Tissue Transglutaminase (tTG) IgG Ordering Recommendation Recommended single screening test for IgA-deficient individuals with suspected celiac disease. (IgA testing recommended to identify IgA deficiency.) May aid in monitoring adherence to gluten-free diet in celiac disease confirmed patients. Mnemonic Methodology Semi-Quantitative Enzyme-Linked Immunosorbent Assay Performed Mon-Sat Reported 1-2 Days New York DOH Approval Status This test is New York DOH approved. Specimen Required Patient Preparation: Collect: Serum separator tube (SST). Specimen Preparation: Remove serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to a Standard Transport Tube. (Min: 0.5 mL) Storage/Transport Temperature: Refrigerated Unacceptable Conditions: Refrigerated. Remarks: Plasma. Hemolyzed or severely lipemic specimens. Stability: After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year Reference Interval 5 U/mL or less 6-9 U/mL Negative Weak Positive 10 U/mL or greater Positive Interpretive Data The tTG IgG assay may aid in the diagnosis of gluten-sensitivity enteropathy (i.e., celiac disease, dermatitis herpetiformis) in tTG IgA negative patients with confirmed IgA deficiency. A negative tTG IgG test alone does not rule out gluten-sensitive enteropathy. Note Human recombinant tTG antigen is utilized in this assay CPT Code 86364 Components Component Chart Name Tissue Transglutaminase (tTG) Ab, IgA Component Test Code 0056009 LOINC 56537-4 Aliases Tissue Transglutaminase Transglu taminase tTG tTG IgG